11/15
07:07 am
alrn
Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]
High
Report
Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]
11/14
04:21 pm
alrn
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
High
Report
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
04:15 pm
alrn
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
High
Report
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13
01:26 pm
alrn
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]
Low
Report
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]
11/13
07:00 am
alrn
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Medium
Report
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
10/31
07:30 am
alrn
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Medium
Report
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
10/12
09:00 am
alrn
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Low
Report
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis